Early tolerability and safety of fingolimod in clinical practice

Journal of the Neurological Sciences

Volumn 323, Issue 1-2, 2012, Pages 167-172

  Ontaneda, Daniel ^a   Hara Cleaver, Claire ^a   Rudick, Richard A ^a   Cohen, Jeffrey A ^a   Bermel, Robert A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adverse effects; Clinical practice; Disease modifying agents; Fingolimod; Multiple sclerosis; Tolerability

Indexed keywords

FINGOLIMOD;

ADULT; ARTICLE; BRADYCARDIA; CHEST TIGHTNESS; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; SCREENING;

ADULT; BRADYCARDIA; CHEST PAIN; DRUG SUBSTITUTION; FEMALE; HEADACHE; HUMANS; HYPERTENSION; LYMPHOPENIA; MACULAR EDEMA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NAUSEA; PATIENT ACCEPTANCE OF HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; PROPYLENE GLYCOLS; RETROSPECTIVE STUDIES; SPHINGOSINE;

EID: 84867851395     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.09.009     Document Type: Article

References (17)

1. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 2010 91 101
2. V. Brinkmann, M.D. Davis, C.E. Heise, R. Albert, S. Cottens, and R. Hof The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 2002 21453 21457
3. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, and P. Calabresi FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
4. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, and X. Montalban Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
5. NDA 02257 FDA approved labeling text for Gilenya (fingolimod) capsules Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022527s000lbl.pdf 2010
6. R.A. Rudick, G. Cutter, and S. Reingold The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials Mult Scler 8 2002 359 365
7. C.E. Schwartz, T. Vollmer, and H. Lee Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group Neurology 52 1999 63 70
8. K. Kroenke, R.L. Spitzer, and J.B. Williams The PHQ-9: validity of a brief depression severity measure J Gen Intern Med 16 2001 606 613
9. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group Health Policy 16 1990 199 208
10. W. Collins, J. Cohen, P. O'Connor, A. de Vera, L. Zhang-Auberson, and F.J. Jin Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies (P843) Mult Scler 16 2010 S295
11. J.P. DiMarco, P. O'Connor, and J.A. Cohen First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS) (P830) Mult Scler 16 2010 S290 (16 (Suppl 10):S290)
12. P.S. Espinosa, and J.R. Berger Delayed fingolimod-associated asystole Mult Scler 17 2011 1387 1389
13. L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, and C.H. Polman FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 2006 1124 1140
14. A. Horga, J. Castillo, and X. Montalban Fingolimod for relapsing multiple sclerosis: an update Expert Opin Pharmacother 11 2010 1183 1196
15. M. Salvadori, K. Budde, B. Charpentier, J. Klempnauer, B. Nashan, and L.M. Pallardo FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia Am J Transplant 6 2006 2912 2921
16. H. Tedesco-Silva, P. Szakaly, A. Shoker, C. Sommerer, N. Yoshimura, and F.P. Schena FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study Transplantation 84 2007 885 892
17. A.J. Hoitsma, E.S. Woodle, D. Abramowicz, P. Proot, Y. Vanrenterghem on behalf of the FTY720 Phase II Transplant Study Group FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study Nephrol Dial Transplant 26 2011 3802 3805